Full Press Release Details
Oncolytics Biotech Inc. Announces Details of 2015 Annual Meeting of Shareholders
CALGARY, June 5, 2015 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) announced today that its 2015 Annual Meeting of Shareholders will be held on Monday June 8th, 2015 at 2:30 pm
CT (3:30 pm ET) at the Wyndham Grand Chicago Riverfront, 71 East Upper Wacker Drive, Chicago, Illinois.
Following the business portion of the meeting, Dr. Brad Thompson, President
and CEO of Oncolytics, will discuss recent progress in the development of REOLYSIN as a potential cancer therapeutic.
A live audio webcast of the presentation will begin at approximately 3:00
pm CT (4:00 pm ET) and be available at: http://event.on24.com/r.htme=1002306&s=1&k=A26C8F4F6DCBD6F8AE9F2E855714E514 or
on the company's website at www.oncolyticsbiotech.com. It is recommended that listeners log on 10 minutes in advance of the presentation
to register and download any necessary software.
An audio replay will be accessible following the presentation at http://www.oncolyticsbiotech.com/for-investors/presentations.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release and the presentation related thereto contain forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including
the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to
the success of its research and development programs in 2015 and beyond, the Company's planned operations, the value of the additional
patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs;
and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize REOLYSIN , uncertainties related to the research
and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom, Nick Hurst, 300 5th Ave. SW, 10th
Floor, Calgary, Alberta, T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael Moore, San
Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor, New York,
NY, 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 05-JUN-15